# US 2017/0281673 A1 · Use of nitrite salts for the treatment of cardiovascular conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281673 A1
- Document ID: US20170281673A1
- Status: Published application
- Kind: A1
- Application number: 15/630,017
- Filed: 2017-06-22
- Published: 2017-10-05
- Earliest claimed: 2003-07-09
- Assignees: The Government of the U.S.A. as represented by the Sec. of the Dept. of Health and Human Services; Loma Linda University; Wake Forest University
- Applicants: The Government of the U.S.A. as represented by the Sec. of the Dept. of Health and Human Services; Loma Linda University; Wake Forest University
- Inventors: Mark T. Gladwin; Alan N. Schechter; Christian J. Hunter; Gordon G. Power; Daniel B. Kim-Shapiro; Richard O. Cannon, III
- Web page: https://patentgrep.com/patent/US20170281673A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 33/00: Antiparasitic agents
- A61P 33/06: Antimalarials
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.

## Claims

### Claim 1

A method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a non-acidified pharmaceutically acceptable nitrite salt.

### Claim 2 (depends on 1)

The method of claim 1, wherein the non-acidified pharmaceutically acceptable nitrite salt is an alkali metal nitrite.

### Claim 3 (depends on 1)

The method of claim 1, wherein the non-acidified pharmaceutically acceptable nitrite salt is a salt of an anionic nitrite with a cation, which is selected from sodium, potassium, and arginine.

### Claim 4 (depends on 1)

The method of claim 1, wherein the non-acidified pharmaceutically acceptable nitrite salt is non-acidified sodium nitrite.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration is by an administration route, in which the non-acidified pharmaceutically acceptable nitrite salt contacts blood of the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein the administration route is selected from the group consisting of intravenous, intramuscular, rectal, ex vivo, intraocular, intraperitoneal, intraarterial, subcutaneous, and into a cardiopulmonary bypass circuit.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject has primary pulmonary hypertension.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has secondary pulmonary hypertension.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has primary and secondary pulmonary hypertension.

### Claim 10 (depends on 1)

The method of claim 1, wherein a circulating concentration of the non-acidified pharmaceutically acceptable nitrite salt is of 0.6 to 240 μM.

### Claim 11 (depends on 1)

The method of claim 1, wherein a circulating concentration of the non-acidified pharmaceutically acceptable nitrite salt is no more than about 100 μM.

### Claim 12 (depends on 1)

The method of claim 1, wherein a circulating concentration of the non-acidified pharmaceutically acceptable nitrite salt is no more than about 50 μM.

### Claim 13 (depends on 1)

The method of claim 1, wherein a circulating concentration of the non-acidified pharmaceutically acceptable nitrite salt is no more than about 20 μM.

### Claim 14 (depends on 1)

The method of claim 1, wherein said administering decreases blood pressure in the lungs of the subject, increases vasodilation or both.

### Claim 15 (depends on 1)

The method of claim 1, wherein said administering induces production in the subject of no more than about 25% methemoglobin.

### Claim 16 (depends on 1)

The method of claim 1, said administering induces production in the subject of no more than about 20% methemoglobin.

### Claim 17 (depends on 1)

The method of claim 1, said administering induces production in the subject of no more than about 15% methemoglobin.

### Claim 18 (depends on 1)

The method of claim 1, said administering induces production in the subject of no more than about 10% methemoglobin.

### Claim 19 (depends on 1)

The method of claim 1, said administering induces production in the subject of no more than about 5% methemoglobin.

### Claim 20 (depends on 1)

The method of claim 1, wherein the non-acidified pharmaceutically acceptable nitrite salt is administered with at least one additional agent

### Claim 21 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 22 (depends on 1)

The method of claim 1, wherein the subject further has a hemolytic condition and wherein said administering treats said hemolytic condition.

### Claim 23 (depends on 22)

The method of claim 22, wherein said hemolytic condition is sickle cell disease.
